VKTX
Viking Therapeutics, Inc.Company Information
- Company Name
- Viking Therapeutics, Inc.
- CIK
- CIK0001607678
- Category
- Large accelerated filer
- Ticker: Exchange
- VKTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- VKTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-10
- Last sale
- 2026-07-29
- Shares purchased (TTM)
- 4,475
- Shares sold (TTM)
- 664,041
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 75,484,282
- Shares outstanding
- 116,262,723
- Ownership
- 64.93%
Earnings Market Reaction
- Filing date
- 2026-07-29
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 126 | 118 | 166 | 100 | 34 | 38 | 27 | 50 | 44 | 196 | 56 | 37 | ||||||
| Available For Sale Securities Debt Securities Current | 376 | 485 | 540 | 614 | 774 | 814 | 876 | 880 | 898 | 767 | 307 | 339 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 0 | 1 | 3 | 1 | ||||||
| Assets Current | 518 | 608 | 716 | 739 | 827 | 866 | 907 | 937 | 946 | 966 | 367 | 381 | ||||||
| Operating Lease Right Of Use Asset | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Restricted Cash Noncurrent | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 522 | 608 | 716 | 739 | 828 | 867 | 908 | 938 | 947 | 968 | 368 | 383 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 69 | 67 | 53 | 4 | 5 | 8 | 10 | 0 | 11 | 5 | 8 | 6 | ||||||
| Other Accrued Liabilities Current | 40 | 39 | 23 | 21 | 26 | 11 | 17 | 25 | 14 | 27 | 11 | 7 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 110 | 106 | 77 | 26 | 32 | 20 | 27 | 26 | 25 | 33 | 19 | 13 | ||||||
| Operating Lease Liability Noncurrent | 4 | - | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Noncurrent | 4 | - | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 114 | 106 | 77 | 26 | 32 | 20 | 28 | 26 | 26 | 34 | 20 | 14 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Value | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7 | -7 | ||||||
| Additional Paid In Capital Common Stock | 1,543 | 1,509 | 1,486 | 1,403 | 1,395 | 1,381 | 1,369 | 1,362 | 1,351 | 1,341 | 734 | 729 | ||||||
| Retained Earnings Accumulated Deficit | -1,134 | -1,006 | -848 | -690 | -599 | -534 | -488 | -452 | -428 | -405 | -378 | -353 | ||||||
| Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -1 | -1 | 0 | 0 | -0 | -0 | -1 | 2 | -2 | -2 | -0 | -1 | ||||||
| Stockholders Equity | 408 | 502 | 639 | 713 | 795 | 847 | 880 | 911 | 921 | 934 | 348 | 368 | ||||||
| Liabilities And Stockholders Equity | 522 | 608 | 716 | 739 | 828 | 867 | 908 | 938 | 947 | 968 | 368 | 383 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 117 | 116 | 115 | 112 | 112 | 112 | 112 | 111 | 111 | 110 | 100 | 100 | ||||||
| Shares Outstanding | 117 | 116 | 115 | 112 | 112 | 112 | 112 | 111 | 111 | 110 | 100 | 100 | ||||||
| Treasury Stock Common Shares | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialViking Therapeutics, Inc. (VKTX) — SEC Financial Statements & Analysis
Viking Therapeutics, Inc. (VKTX) is a pharmaceutical preparations company, incorporated in DE. Viking Therapeutics, Inc. trades on Nasdaq as: VKTX. Viking Therapeutics, Inc. (VKTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29. Based on that filing, Viking Therapeutics, Inc. carries a market cap of $4.54B, a P/E ratio of -8.48x, a P/B ratio of 11.11x, an enterprise value of $4.41B, and an EV/EBITDA multiple of -7.87x. On profitability, it posts a Return on Equity (ROE) of -88.85%, a Return on Assets (ROA) of -79.24%, and a Return on Invested Capital (ROIC) of -107.27%. Per share, it reports EPS of $-4.60, diluted EPS of $-4.60, free cash flow per share of $-3.60, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 211.75% year-over-year and EPS growth of 200.68% year-over-year. On the balance sheet, it maintains a current ratio of 4.72x, a quick ratio of 4.71x, working capital of $407.91M, a debt-to-equity ratio of 0.28x, a debt ratio of 0.22, an interest coverage ratio of -22.27x, free cash flow of $-418.44M (TTM), and net debt of $-125.75M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.54B
- P/E TTM
- -8.48x
- EPS TTM
- $-4.60
- P/B TTM
- 11.11x
- ROE TTM
- -88.85%
- ROA TTM
- -79.24%
- Debt To Equity
- 0.28x
- Free Cash Flow TTM
- $-418.44M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Viking Therapeutics, Inc. in?
Viking Therapeutics, Inc. (VKTX) operates in the Pharmaceutical Preparations industry.
What exchange does VKTX trade on?
Viking Therapeutics, Inc. (VKTX) trades on the Nasdaq.
Where is Viking Therapeutics, Inc. incorporated?
Viking Therapeutics, Inc. is incorporated in DE.
When was Viking Therapeutics, Inc. (VKTX)'s most recent SEC filing?
Viking Therapeutics, Inc. (VKTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29.
What is VKTX's market cap?
Viking Therapeutics, Inc. (VKTX) has a market capitalization of $4.54B as of 2026-06-30.
What is VKTX's EPS (earnings per share)?
Viking Therapeutics, Inc. (VKTX)'s trailing twelve month EPS is $-4.60 as of 2026-06-30.
What is VKTX's ROE (return on equity)?
Viking Therapeutics, Inc. (VKTX)'s trailing twelve month Return on Equity (ROE) is -88.85% as of 2026-06-30.
What is VKTX's ROA (return on assets)?
Viking Therapeutics, Inc. (VKTX)'s trailing twelve month Return on Assets (ROA) is -79.24% as of 2026-06-30.
What is VKTX's ROIC (return on invested capital)?
Viking Therapeutics, Inc. (VKTX)'s trailing twelve month Return on Invested Capital (ROIC) is -107.27% as of 2026-06-30.
What is VKTX's EV/EBITDA?
Viking Therapeutics, Inc. (VKTX)'s trailing twelve month EV/EBITDA is -7.87x as of 2026-06-30.